{"id":7762,"date":"2020-12-22T06:35:35","date_gmt":"2020-12-22T06:35:35","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-approbation-de-vyzulta-en-colombie-par-son-partenaire-bausch-lomb\/"},"modified":"2020-12-22T06:35:35","modified_gmt":"2020-12-22T06:35:35","slug":"nicox-approbation-de-vyzulta-en-colombie-par-son-partenaire-bausch-lomb","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-en-colombie-par-son-partenaire-bausch-lomb\/","title":{"rendered":"Nicox : Approbation de VYZULTA\u00ae en Colombie par son partenaire Bausch + Lomb"},"content":{"rendered":"<p>Sophia Antipolis, France<\/p>\n<p><strong>Nicox SA<\/strong> (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire Bausch + Lomb a re\u00e7u l\u2019approbation de mise sur le march\u00e9 en Colombie de la solution ophtalmique de latanoprost\u00e8ne bunod, 0,024% sous le nom de sp\u00e9cialit\u00e9 CLIROPTA<sup>\u00ae<\/sup> (produit commercialis\u00e9 aux Etats-Unis sous le nom VYZULTA<sup>\u00ae<\/sup>).<\/p>\n<p>VYZULTA est commercialis\u00e9 aux Etats-Unis, au Canada et en Argentine et approuv\u00e9 pour commercialisation dans cinq autres territoires &#8211; Colombie, Hong Kong, Mexique, Taiwan et Ukraine &#8211; pour la r\u00e9duction de la pression intraoculaire (PIO) chez les patients atteints de glaucome \u00e0 angle ouvert ou d&rsquo;hypertension oculaire. Bausch + Lomb soumet des demandes d\u2019approbation dans des territoires o\u00f9 les donn\u00e9es cliniques de l\u2019enregistrement am\u00e9ricain peuvent \u00eatre utilis\u00e9es pour approbation par les autorit\u00e9s r\u00e9glementaires locales.<\/p>\n<p>Selon les termes de l\u2019accord de concession de licence exclusif avec Bausch + Lomb, Nicox re\u00e7oit des redevances nettes croissantes de 6% \u00e0 12% sur les ventes mondiales de VYZULTA et des paiements d\u2019\u00e9tape potentiels pouvant atteindre un montant de 150 millions de dollars.<\/p>\n<p>Bausch + Lomb est une soci\u00e9t\u00e9 mondiale leader en sant\u00e9 oculaire de Bausch Health Companies Inc. (NYSE\/TSX: BHC).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sophia Antipolis, France Nicox SA (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire Bausch + Lomb a re\u00e7u l\u2019approbation de mise sur le march\u00e9 en Colombie de la solution ophtalmique de latanoprost\u00e8ne bunod, 0,024% sous le nom de sp\u00e9cialit\u00e9 CLIROPTA\u00ae (produit commercialis\u00e9 aux Etats-Unis sous le [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-7762","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox : Approbation de VYZULTA\u00ae en Colombie par son partenaire Bausch + Lomb - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-en-colombie-par-son-partenaire-bausch-lomb\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox : Approbation de VYZULTA\u00ae en Colombie par son partenaire Bausch + Lomb - Nicox\" \/>\n<meta property=\"og:description\" content=\"Sophia Antipolis, France Nicox SA (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire Bausch + Lomb a re\u00e7u l\u2019approbation de mise sur le march\u00e9 en Colombie de la solution ophtalmique de latanoprost\u00e8ne bunod, 0,024% sous le nom de sp\u00e9cialit\u00e9 CLIROPTA\u00ae (produit commercialis\u00e9 aux Etats-Unis sous le [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-en-colombie-par-son-partenaire-bausch-lomb\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-22T06:35:35+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-en-colombie-par-son-partenaire-bausch-lomb\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-en-colombie-par-son-partenaire-bausch-lomb\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox : Approbation de VYZULTA\u00ae en Colombie par son partenaire Bausch + Lomb\",\"datePublished\":\"2020-12-22T06:35:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-en-colombie-par-son-partenaire-bausch-lomb\\\/\"},\"wordCount\":215,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-en-colombie-par-son-partenaire-bausch-lomb\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-en-colombie-par-son-partenaire-bausch-lomb\\\/\",\"name\":\"Nicox : Approbation de VYZULTA\u00ae en Colombie par son partenaire Bausch + Lomb - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-12-22T06:35:35+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-en-colombie-par-son-partenaire-bausch-lomb\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox : Approbation de VYZULTA\u00ae en Colombie par son partenaire Bausch + Lomb - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-en-colombie-par-son-partenaire-bausch-lomb\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox : Approbation de VYZULTA\u00ae en Colombie par son partenaire Bausch + Lomb - Nicox","og_description":"Sophia Antipolis, France Nicox SA (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire Bausch + Lomb a re\u00e7u l\u2019approbation de mise sur le march\u00e9 en Colombie de la solution ophtalmique de latanoprost\u00e8ne bunod, 0,024% sous le nom de sp\u00e9cialit\u00e9 CLIROPTA\u00ae (produit commercialis\u00e9 aux Etats-Unis sous le [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-en-colombie-par-son-partenaire-bausch-lomb\/","og_site_name":"Nicox","article_published_time":"2020-12-22T06:35:35+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-en-colombie-par-son-partenaire-bausch-lomb\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-en-colombie-par-son-partenaire-bausch-lomb\/"},"author":{"name":"","@id":""},"headline":"Nicox : Approbation de VYZULTA\u00ae en Colombie par son partenaire Bausch + Lomb","datePublished":"2020-12-22T06:35:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-en-colombie-par-son-partenaire-bausch-lomb\/"},"wordCount":215,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-en-colombie-par-son-partenaire-bausch-lomb\/","url":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-en-colombie-par-son-partenaire-bausch-lomb\/","name":"Nicox : Approbation de VYZULTA\u00ae en Colombie par son partenaire Bausch + Lomb - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2020-12-22T06:35:35+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-en-colombie-par-son-partenaire-bausch-lomb\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7762","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=7762"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7762\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=7762"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=7762"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=7762"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}